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Difficulty in assaying colistin
methanesulphonate
The world is facing a growing threat from the
emergence of multidrug-resistant Gram-negative
bacteria, in particular Pseudomonas aeruginosa
and Acinetobacter baumannii, some isolates of
which are resistant to almost all currently
available antibiotics, except colistin [1,2]. Colis-
tin is used increasingly as ‘salvage’ therapy for
infections caused by these bacteria in critically
ill patients. There are two forms of colistin
available commercially, i.e., colistin sulphate for
topical use, and sodium colistin methanesulpho-
nate (CMS) for inhalation and parenteral use.
However, measurement of CMS in biological
samples is difficult because of its complex
chemistry [1].
The recent Research Note in CMI by Wootton
et al. [3] described a microbiological assay for
CMS in serum and urine samples from patients
with cystic fibrosis. However, this method is
unable to distinguish between CMS and the
colistin formed by the hydrolysis of CMS. There-
fore, factors such as the complex conversion of
CMS to colistin in vivo, as well as during incuba-
tion of microbiological assays at 37C in vitro, and
the different activities of CMS and colistin may
affect the accuracy and reproducibility of the
microbiological assay.
Colistin and CMS have different structures;
colistin is a polycation and CMS is a polyanion
at physiological pH [1]. Colistin is 2–4-fold more
active against P. aeruginosa than is CMS [4]. The
presence of colistin in plasma from cystic
fibrosis patients shortly after intravenous admin-
istration of CMS has now been demonstrated
[5], as has the rapid conversion of CMS to
colistin after intravenous administration of CMS
to rats [6]. This conversion has been verified
in vitro in human plasma at 37C, but occurred
more slowly than in vivo [7]. Therefore, the
colistin formed from CMS in plasma, serum and
urine in vivo, and during the microbiological
assays (37C incubation for 24 h) in vitro, will
affect the accuracy and reproducibility of the
microbiological assays, which are based on total
antibacterial activity within the samples. It is
presumed that plasma or serum samples contain
many intermediate CMS hydrolysis products
with one, two, three or four methanesulphonate
groups located at different amine groups of
colistin [7]. CMS has five methanesulphonate
groups and is used for preparing calibration
curves for microbiological assays. As the con-
version of CMS to colistin requires that CMS
loses all five of its methanesulphonate groups,
this process occurs less rapidly than for the
intermediates, which have fewer methanesul-
phonate groups. Hence, theoretically, samples
containing such intermediates will produce col-
istin more rapidly during incubation in the
microbiological assays, compared with the sam-
ples containing CMS for calibration curves.
Given that colistin is more active than CMS, it
is very likely that the concentration of ‘CMS’ in
biological samples could be overestimated. It is
not known whether the various intermediates
have different antibacterial activities and diffu-
sion characteristics in the agar plates used in
microbiological assays.
A literature review of colistin reveals that the
complex chemistry of CMS, as well as the
differences between CMS and colistin (base or
sulphate), in terms of stability, pharmacokinetics
and pharmacodynamics, have not been fully
recognised. It should be noted that CMS, not
colistin sulphate, as described by Wootton et al.
[3], hydrolyses to form a complex mixture of
partially methanesulphonated intermediates plus
colistin. In addition, unlike high-performance
liquid chromatography assays [8,9], microbiolo-
gical assays cannot measure the concentrations
of different colistin components, such as colistin
A and B.
In summary, regardless of whether microbio-
logical or high-performance liquid chromatogra-
phy assays are employed to measure the
concentrations of CMS and colistin in biological
samples, it is important to appreciate the
complex chemistry of CMS and its conver-
sion to colistin, both in vitro and in vivo.
Accurate concentration measurements of
CMS and the colistin formed in biological
samples are essential for investigating the phar-
macokinetics and pharmacodynamics of these
compounds.
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